Full Text View
Tabular View
No Study Results Posted
Related Studies
Intron-A/Aldara Combination Therapy for Basal Cell Carcinoma (BCC)
This study is ongoing, but not recruiting participants.
Study NCT00581425   Information provided by The University of Texas Health Science Center, Houston
First Received: December 21, 2007   Last Updated: April 29, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Basal Cell Carcinoma
Additional conditions recognized in this trial
Carcinoma
Carcinoma, Basal Cell
More general conditions related to this trial
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Basal Cell
Neoplasms, Glandular and Epithelial
Interventions listed in this trial
Imiquimod and Interferon alpha
Additional drug interventions recognized in this trial
Imiquimod
Interferon Alfa-2a
Interferon-alpha
Interferons
More general drug interventions related to this trial
Adjuvants, Immunologic
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Anti-Infective Agents
Antineoplastic Agents
Antiviral Agents
Growth Inhibitors
Growth Substances
Immunologic Factors
Interferon Inducers
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
The University of Texas Health Science Center, Houston


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services